Records containing: Melanoma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2025-01-14A Phase Ib/II Randomised Open Label Study of BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib Compared to Pembrolizumab or Dabrafenib/Trametinib Alone, in Patients With Advanced Non-resectable (Stage IIIc) or Metastatic (Stage IV) Melanoma
-
CLINICAL_TRIALS study record update · 2025-01-06A Multi-center, Open-label Phase II Study to Evaluate the Safety and Efficacy of YH003 in Combination with Toripalimab (anti-PD-1 MAb) in Patients with Unresectable/metastatic Melanoma and Pancreatic Ductal Adenocarcinoma (PDAC)
-
CLINICAL_TRIALS study record update · 2025-01-01Phase II Study Investigating the Efficacy of Neoadjuvant Dual Checkpoint Inhibition and Cryoablation Therapy in Children, Adolescents, and Young Adults With Relapsed/Refractory Solid Tumors
-
CLINICAL_TRIALS study record update · 2024-12-30Botensilimab and Balstilimab Expanded Access Program
-
CLINICAL_TRIALS study record update · 2024-12-27A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2024-12-27An Open-Label, Dose-Escalation Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Modakafusp Alfa (TAK-573) as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
-
CLINICAL_TRIALS study record update · 2024-12-24Mature Dendritic Cell Vaccination Against Mutated Antigens in Patients With Advanced Melanoma
-
CLINICAL_TRIALS study record update · 2024-12-24A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients With Cancer
-
CLINICAL_TRIALS study record update · 2024-12-20Phase 1/2 Open Label, Safety and Preliminary Efficacy Study of a Live Biotherapeutic Product (CJRB-101) in Combination With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
-
CLINICAL_TRIALS study record update · 2024-12-19A Phase 2, Open-label, Multicenter Study of IBI363 (PD1-IL2m) in Subjects with Advanced Solid Malignancies
-
CLINICAL_TRIALS study record update · 2024-12-18The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)
-
CLINICAL_TRIALS study record update · 2024-12-11A Phase Ib Study, Evaluating the Safety, Tolerance and Efficacy of PRJ1-3024 Capsules in China Subjects with Unresectable Local Advanced or Metastatic Melanoma
-
CLINICAL_TRIALS study record update · 2024-12-06Cognitive Function in Patients Treated for Melanoma With Adjuvant Immune Checkpoint Inhibitors: A Controlled Prospective Observational Study
-
CLINICAL_TRIALS study record update · 2024-12-06Family History App in Personalized Medicine (FHAMe): A Pilot Randomized Controlled Trial
-
CLINICAL_TRIALS study record update · 2024-12-04PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9
-
CLINICAL_TRIALS study record update · 2024-12-04Ontario-wide Cancer TArgeted Nucleic Acid Evaluation
-
CLINICAL_TRIALS study record update · 2024-12-04Controlled Dietary Interventions in Patients with Melanoma
-
CLINICAL_TRIALS study record update · 2024-12-03Positron Emission Tomography Repeatability Evaluation of Tissue Zirconium 89Zr Crefmirlimab Berdoxam
-
CLINICAL_TRIALS study record update · 2024-11-29A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC and Embedded Phase I/IIa Trial With Tumor Lysate Particle Only (TLPO) Vaccine in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence.
-
CLINICAL_TRIALS study record update · 2024-11-27A Randomised Trial of Post-operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck
-
CLINICAL_TRIALS study record update · 2024-11-27Phase II Study of Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma
-
CLINICAL_TRIALS study record update · 2024-11-15A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, Preliminary Clinical Activity and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2024-11-15A First-In-Human Phase 1/2 Open-Label Study of Intravenous ST-067, Subcutaneous ST-067 with or Without Obinutuzumab Pre-Treatment, and ST-067 in Combination with Pembrolizumab in Subjects with Advanced Solid Malignancies
-
CLINICAL_TRIALS study record update · 2024-11-15Impact of Physical Activity on Immunotherapy-induced Toxicities in Melanoma Management
-
CLINICAL_TRIALS study record update · 2024-11-14Multicenter Phase 1b/2 Trial Testing Neoadjuvant Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma - MARIANE